Key facts
- Notable investors include Everywhere Ventures, 51Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Axo Longevity
- ·The full record, as it builds
Funding rounds
No funding rounds for Axo Longevity are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axo Longevity
Provider of clinical laboratory testing services designed for the diagnosis and monitoring of autoimmune, hematologic, metabolic, and cardiovascular conditions. The company offers a range of tests, including antibody screening, blood typing, blood counts, lipid profiling, and biomarker-based biological age estimation, enabling healthcare professionals with diagnostic data that enables assessment and management of medical conditions.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Employees
- 5
- Website
- axolongevity.com/
- Ownership
- Privately Held (backing)
Axo Longevity doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axo Longevity shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axo Longevity in its N-PORT filings yet. We sweep new filings monthly.